You are now leaving GSK’s website

You are now leaving a GSK Website. By clicking this link, you will be taken to a website that is not owned or controlled by GSK, and GSK is not responsible for the content provided on that site.


Go back

Exacerbations with Relvar

Asthma control isn’t just about reducing symptoms – it’s about reducing the likelihood of exacerbations too.

With Relvar, asthma patients can reduce their rate of exacerbations vs both BUD/Form and ICS, as proven in real-world and clinical settings, respectively.1,2

overall exacerbations infographic
severe exacerbations infographic
Clinical Findings exacerbations infographic

This graph has been independently created by GSK from the original data. The same results were first published in Bateman ED, et al. Thorax 2014;69:312–319.

Discover Relvar


BUD, budesonide; CI, confidence interval; Form, formoterol; ICS, inhaled corticosteroid.

  1. Averell CM, et al. Presented virtually at the American College of Allergy, Asthma & Immunology annual meeting 2020.
  2. Bateman ED, et al. Thorax 2014;69:312–319.

RELVAR Ellipta was created in collaboration with

Innoviva logo

Adverse events should be reported directly to the Health Products Regulatory Authority (HPRA) on their website: Adverse events should also be reported to GlaxoSmithKline on 1800 244 255.

Relvar is a registered trademark of the GlaxoSmithKline group of companies

PM-IE-FFV-WCNT-230007 June 2023